Chagas disease, caused by the kinetoplastid parasite Trypanosoma cruzi, affects between 6 and 7 million people worldwide, with an estimated 300,000 to 1 million of these cases in the United States. In the chronic phase of infection, T. cruzi can cause severe gastrointestinal and cardiac disease, which can be fatal. Currently, only benznidazole is clinically-approved by the FDA for pediatric use to treat this infection in the USA. Toxicity associated with this compound has driven the search for new anti-Chagas agents. Drug repurposing is a particularly attractive strategy for neglected diseases, as pharmacological parameters and toxicity are already known for these compounds, reducing costs and saving time in the drug development pipeline. Here, we screened ~ 12,000 compounds from the ReFRAME library, a collection of drugs or compounds with confirmed clinical safety, against T. cruzi. We identified 7 compounds of interest with potent in vitro activity against the parasite with a therapeutic index of 10 or greater, including the previously-unreported activity of the antiherpetic compound 348U87. These results provide the framework for further development of new T. cruzi leads that can potentially move quickly to the clinic.
Introduction
Trypanosoma cruzi, the causative agent of Chagas disease, is a protozoan parasite that is primarily transmitted to humans via triatomine insects (known as kissing bugs) during a blood meal. Infection by T. cruzi manifests initially in an acute phase of infection, and if left untreated, proceeds to a chronic phase (1) . During the acute phase, mild or unremarkable symptoms such as fever, fatigue, rash, headache or swelling at the site of the triatome bite may present. When left untreated, the primary infection usually resolves in weeks, but residual parasites remain in the host's body evolving to the chronic phase. Over the span of years to decades, approximately 30% of those infected individuals will manifest cardiac and/or gastrointestinal complications leading to morbidity and mortality (2) . Current treatment options are very limited for Chagas disease: only benznidazole is clinically-approved for pediatric use in the case of acute T. cruzi infections in the United States. Benznidazole and nifurtimox are available off-label via the CDC for compassionate use for all other cases of this infection. However, severe side-effects associated with the use of these medications leads to high levels of patient discontinuation of treatment. Furthermore, the usefulness of benznidazole in the chronic phase of infection is disputed within the Chagas research community (3) (4) (5) .
Limited efforts from the pharmaceutical industry to develop a medication for T. cruzi infections further complicates progress towards anti-Chagas agents better than benznidazole and nifurtimox. Rising costs and high levels of failure of drug molecules in clinical trials due to adverse events and lack of efficacy present further general barriers to the development of medications. One cost-effective strategy involves repurposing existing drugs with known toxicity and pharmacokinetic profiles for other indications (6) .
This has the potential to speed up drug development efforts, reduce costs and lower the chance of adverse events presenting in clinical trials. The ReFRAME (Repurposing, Focused Rescue, and Accelerated Medchem) library, a comprehensive set of molecules with tested clinical safety, has been previously used to identify potential drug repurposing hits for neglected tropical diseases (7, 8) . In this work, we screened 7,680 compounds from this library against the medically relevant intracellular, amastigote form of T. cruzi infecting mouse myoblasts using a high-throughput, phenotypic cellular imaging assay that our group has successfully used in previous studies to identify novel antitrypanosomal agents (9) (10) (11) . We identified seven compounds with suitable selectivity indexes (SIs) for drug repurposing; two of these, the antiherpetic drug previously been reported as anti-Chagas compounds and may target the parasite through a novel mechanism. These molecules form an attractive collection of lead molecules for potential drug repurposing to treat Chagas disease.
Results
Primary screening of the ReFRAME library against T. cruzi using a high-content imaging assay.
Compounds from the ReFRAME library were pre-spotted on 1536 clear-bottom black well plates in 100% dimethylsulfoxide (DMSO) for a final concentration of 10 µM in 10 µL final volume (and 0.1% DMSO final concentration). C212 mouse myoblasts and CA-I/72 strain T. cruzi trypomastigotes were added to the plate in a 15:1 infection ratio and incubated for 72 hours at 37°C and 5% CO2. Cells were then fixed with 4% paraformaldehyde (final concentration), and stained with 5 µg/ml of 4',6-diamidino-2phenylindole (DAPI) to highlight the nuclei from the host cells and parasites. Using an ImageXpress MicroXL automated microscope (10x magnification setting), fluorescence images of C2C12 and T. cruzi amastigote nuclei were acquired for each well, and the number of host cell nuclei and amastigote nuclei were automatically determined using a custom image analysis module as previously described (9-11) ( Figure 1 ). Infection levels were calculated as a ratio of the number of T. cruzi amastigotes per C2C12 host cell as determined by nuclei counting. Compound toxicity was determined by dividing the number of host cell nuclei in a drug-treated well to the average of the vehicle controls. For both infection ratios and cell viability ratios, values were normalized to the vehicle controls to determined percent activity and toxicity, respectively. Control wells containing uninfected C2C12 cells, infected C2C12 cells with 0.1% DMSO, and infected C2C12 cells with 0.1% DMSO and 50 µM benznidazole were prepared in each plate for data normalization. The mean Z' for the 10 plates tested was 0.52 with a standard error of 0.01. Hit selection cutoffs for the primary screen were set at 70% antiparasitic activity (70% parasite reduction compared to untreated controls) and 50% host cell viability at 10 µM compound compared to untreated controls (represents approximately 3 standard deviations from the average of the untreated controls). We identified 238 compounds (2% of the total library) that met these selection criteria. A summary of the primary screening data is shown in Figure 2 .
Counter-screen of 238 hits in dose response
To validate the hits obtained from our primary screen, compounds were respotted in duplicate in a 10-point, 3-fold dilution dose response, with 10 µM as the highest concentration of inhibitor. Using the high-content imaging assay, 238 primary hits were retested in duplicate. We identified seven compounds of interest using the following cutoff criteria: at least 70% antiparasitic activity at a given drug concentration in one of the two dose response replicates and a therapeutic index of 10 or greater. Half maximal effective concentration (EC50), half maximal cytotoxic concentration (CC50) and selective index (SI; defined by the ratio of CC50 to EC50) for validated hits are shown in Table 1 , their dose response curves are shown in Figure 3 
Discussion
Given the toxicity of currently available drugs to treat T. cruzi infection, research efforts have been made to explore additional candidate molecules against the parasite.
In this work, we screened a drug repurposing library for compounds with anti-Chagasic activity. We identified 7 molecules as having potent in vitro activity against T. cruzi and a SI of at least 10 against C2C12 cardiomyocyte host cells.
As validation for our assay, we identified a number of compounds from classes 
Materials and Methods

Cells.
C2C12 mouse myoblasts (ATCC CRL-1772) and CA-I/72 T. cruzi (kindly donated by J. analyzed automatically using a custom image analysis module (9, 11) .
Software.
Chemical structures were prepared using ChemDraw Professional 18.1 (Perkin Elmer).
EC50 and CC50 curves were generated using GraphPad Prism 8 (GraphPad Software).
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